- Savara ( NASDAQ: SVRA ) Badrul Chowdhury resigned as chief medical officer, effective Sept. 9.
- "His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future," said Savara Chair and CEO Matt Pauls.
- A day ago, the company said that molgramostim received promising innovative medicine (PIM) designation in the U.K. for autoimmune pulmonary alveolar proteinosis, a type of rare lung disease.
For further details see:
Savara's chief medical officer resigns